These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21232719)

  • 1. Sex-related outcomes after drug-eluting stent: should we "never mind" or "mind" the gap?
    Mehran R; Kini AS
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1260-1. PubMed ID: 21232719
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis.
    Mikhail GW; Gerber RT; Cox DA; Ellis SG; Lasala JM; Ormiston JA; Stone GW; Turco MA; Joshi AA; Baim DS; Colombo A
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1250-9. PubMed ID: 21232718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stent implantation in a real-world population: a comparison with paclitaxel-eluting stents: the PORI registry.
    Karjalainen PP; Ylitalo A; Airaksinen JK; Nammas W
    J Interv Cardiol; 2011 Feb; 24(1):1-8. PubMed ID: 21039884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of patients with coronary artery disease with biodegradable polymer based paclitaxel-eluting Infinnium coronary stent system: results of 1-year clinical follow-up a single center experience.
    Vedat A; Selcuk G; Refik E; Onur E; Murat C; Burak CA; Murat G; Cemsid D
    Indian Heart J; 2009; 61(3):254-7. PubMed ID: 20503830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year outcomes of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: are they equally good (or bad)?
    Cutlip DE
    Circulation; 2011 Jun; 123(24):2779-81. PubMed ID: 21646497
    [No Abstract]   [Full Text] [Related]  

  • 8. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.
    Räber L; Wohlwend L; Wigger M; Togni M; Wandel S; Wenaweser P; Cook S; Moschovitis A; Vogel R; Kalesan B; Seiler C; Eberli F; Lüscher TF; Meier B; Jüni P; Windecker S
    Circulation; 2011 Jun; 123(24):2819-28, 6 p following 2828. PubMed ID: 21646500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial.
    Verheye S; Agostoni P; Dawkins KD; Dens J; Rutsch W; Carrie D; Schofer J; Lotan C; Dubois CL; Cohen SA; Fitzgerald PJ; Lansky AJ
    JACC Cardiovasc Interv; 2009 Mar; 2(3):205-14. PubMed ID: 19463427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year clinical outcome after treatment of bare-metal stent in-stent restenosis with the paclitaxel-eluting stent in an unselected cohort.
    Beijk MA; Claessen BE; Koch KT; Henriques JP; Baan J; Vis MM; Meesterman M; Tijssen JG; Piek JJ; de Winter RJ
    Int J Cardiol; 2010 Dec; 145(3):608-9. PubMed ID: 20850881
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of left main coronary trifurcation lesions with the paclitaxel drug-eluting stent: mid-term outcomes from a tertiary medical center.
    Shammas NW; Shammas GA; Jerin M; Parikh A; Coin K; Dippel E; Sharis P; Robken J
    J Invasive Cardiol; 2009 Jul; 21(7):321-5. PubMed ID: 19571341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
    Applegate RJ; Hermiller JJ; Sanz M; Doostzadeh J; Pierson W; Su X; Lansky AJ; Sudhir K; Stone GW
    EuroIntervention; 2010 Sep; 6(4):437-46. PubMed ID: 20884430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side balloon stenting of the left main bifurcation: a three-year angiographic follow-up.
    Latif F; Heldman AW; Hennebry TA
    J Interv Cardiol; 2009 Dec; 22(6):547-9. PubMed ID: 19735474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions.
    Lee CW; Park DW; Seung KB; Kim PJ; Park HJ; Kim WJ; Lee JY; Kang SJ; Lee SH; Kim YH; Park SW; Park SJ
    Am J Cardiol; 2011 Apr; 107(7):990-4. PubMed ID: 21296317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence of "obesity paradox" after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry.
    Akin I; Tölg R; Hochadel M; Bergmann MW; Khattab AA; Schneider S; Senges J; Kuck KH; Richardt G; Nienaber CA;
    JACC Cardiovasc Interv; 2012 Feb; 5(2):162-9. PubMed ID: 22361600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mini-crush versus T-provisional techniques in bifurcation lesions: clinical and angiographic long-term outcome after implantation of drug-eluting stents.
    Galassi AR; Tomasello SD; Capodanno D; Barrano G; Ussia GP; Tamburino C
    JACC Cardiovasc Interv; 2009 Mar; 2(3):185-94. PubMed ID: 19463424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year (mid-term) results for unprotected left main coronary artery percutaneous interventions with drug-eluting stents.
    Yarkoni A; Brodsky A; Sabapathy R; Pershad A
    Indian Heart J; 2008; 60(3):195-9. PubMed ID: 19240306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials.
    Garg S; Sarno G; Girasis C; Vranckx P; de Vries T; Swart M; Bressers M; Garcia-Garcia HM; van Es GA; Räber L; Campo G; Valgimigli M; Dawkins KD; Windecker S; Serruys PW
    JACC Cardiovasc Interv; 2011 Jun; 4(6):645-53. PubMed ID: 21700251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.